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Sir,
We thank Dr Ajani and colleagues for their interest in our study
and apologize for not citing their earlier study (Sims-Mourtada
et al, 2006) in our original paper. From the aspect of management
for metastasis in treatment-failure patients, we designed our study
to evaluate the clinical implications of Hedgehog (Hh) signal
activation for oesophageal squamous cell carcinoma (ESCC)
patients who underwent pre-operative chemoradiotherapy (CRT)
and radical surgery. It is unfortunate that we did not cover their
experimental study, because they also revealed that Hh signalling
activation mechanism is partly dependent on the ATP-binding
cassette transporter family and that chemoresistance can be
overcome by inhibitors of Hh pathways (Sims-Mourtada et al,
2007). Their papers have revealed the basic mechanism involved
from experimental study seeking to overcome CRT resistance;
whereas, we looked at the issue from a clinical perspective focusing
on metastasis. In our paper, we have shown that persistent Gli-1
nuclear expression after CRT can predict very much earlier
recurrence and poorer prognosis in ESCC patients; thus this a
potential diagnostic biomarker and therapeutic target for ‘more
aggressive’ cancer cells that can initiate relapse and maintain
disease (Yoshikawa et al, 2008). This is of importance in clinical
management, because high-risk patients can easily be screened by
Gli-1 evaluation. Management of metastasis has been an important
challenge to us, although since 1996 neoadjuvant CRT has shown
improved resectability and a better prognosis in ESCC (Fujiwara
et al, 2005). Hedgehog pathway antagonists have already been
studied in phase I clinical trials in advanced or metastatic skin
basal cell carcinomas. A combination modality of conventional
anti-cancer agents plus Hh pathway antagonists could potentially
abrogate both primary ‘bulk’ tumours and metastases in solid
tumours (Feldmann et al, 2007).
It was pointed out that we did not carry out multivariate
analysis. This was because the number of parameters was more
than one-tenth the number of patients included in this study;
therefore, we considered that a multivariate analysis might result
in misleading conclusions. Thus, we performed a univariate
analysis because of the small number of patients available for this
study. Our findings will need to be confirmed in a larger more
detailed study using multivariate analysis.
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